Nervous System (e.g., Central Nervous System (cns), Etc.) Affecting Patents (Class 514/17.7)
  • Patent number: 10358409
    Abstract: Compositions including certain olefinic ester compounds are generally disclosed. In some embodiments, such compositions are compositions having low toxicity, such as low aquatic toxicity. Therefore, in some embodiments, such compositions can be suitable used as solvents or as part of a solvent system for applications where low toxicity is desirable. Such uses include, but are not limited to, cleaning applications on or near waterways, use in oil or gas recovery, and the like. In some other embodiments, such compositions are treatment fluids for oil wells, and can therefore be introduced into an oil well to remove buildup and other deposits. In some embodiments, the olefinic ester compounds are derived from a natural oil or a natural oil derivative.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: July 23, 2019
    Assignee: Elevance Renewable Sciences, Inc.
    Inventors: Shubhada Dantale, Frederyk Ngantung, Selim Erhan
  • Patent number: 10292584
    Abstract: Systems and methods for detecting onset, presence, and progression of particular states, including hypoxia, include observing eye movements of a subject to and correlating the observed movements to known baseline or hypoxic conditions. A detection system may record eye movement data from a user, compare the eye movement data to a data model comprising threshold eye movement data samples, and from the comparison make a determination whether or not hypoxia, fatigue, or other detrimental conditions are present. The detection system may alert the user to take corrective action if onset or presence of a dangerous condition is detected. The eye movements detected include saccadic and intersaccadic parameters such as intersaccadic drift velocity. Measurements may be collected in situ while the subject is performing normal duties, processed to determine indicators of detrimental conditions, and reported to the subject within a few seconds.
    Type: Grant
    Filed: January 29, 2015
    Date of Patent: May 21, 2019
    Assignee: Dignity Health
    Inventors: Leandro Luigi Di Stasi, Susana Martinez-Conde, Raul Cabestrero, Andres Catena, Michael McCamy, Stephen L. Macknik
  • Patent number: 10258664
    Abstract: Methods and compositions for treating pain are disclosed. The compositions are based on dry powders comprising microparticles of diketopiperazines and an analgesic active agent. The analgesic in the compositions comprises one or more peptide analgesics or derivatives thereof, which are administered to a subject using a pulmonary inhalation drug delivery system comprising a dry powder inhaler and the analgesic composition. The present compositions produce fewer side effects associated with current opioid therapy.
    Type: Grant
    Filed: February 22, 2017
    Date of Patent: April 16, 2019
    Assignee: MannKind Corporation
    Inventors: Andrea Leone-Bay, Richard A. Houghten, Joseph J. Guarneri, Grayson W. Stowell
  • Patent number: 10150794
    Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: December 11, 2018
    Assignee: Onyx Therapeutics, Inc.
    Inventors: Han-Jie Zhou, Congcong M. Sun, Kevin D. Shenk, Guy J. Laidig
  • Patent number: 10100082
    Abstract: The present investigation involves designing of a novel hexapeptide, which spontaneously self-assembles to form nanovesicles in physiological conditions. This peptide not only strongly binds with ?-tubulin near taxol binding site, but also binds with microtubule lattice in-vitro, as well as intracellular microtubule networks. Interestingly, it inhibits amyloid fibril formation upon co-incubation with A? peptide in-vitro and shows excellent neuroprotection against A? infected neuronal cell (PC12). Present invention provides a novel approach to produce a peptide-based therapeutics for neurodegenerative disease.
    Type: Grant
    Filed: March 7, 2016
    Date of Patent: October 16, 2018
    Assignee: Council of Scientific and Industrial Research
    Inventors: Surajit Ghosh, Atanu Biswas, Batakrishna Jana, Saswat Mohapatra, Subhas Chandra Biswas, Suraiya Saleem, Prasenjit Mondal, Anindyasundar Adak, Subhajit Ghosh, Abhijit Saha, Debmalya Bhunia
  • Patent number: 10022417
    Abstract: A peptide having 12 to 60 amino acids and including (a) a sequence of SEQUENCE ID NO: 11, or (b) a fragment of SEQUENCE ID NO: 11 that includes the sequence of SEQUENCE ID NO: 1 or 5, is described for use in improving glycemic management in a mammal. A composition, for example a food product, that includes substantially all of the peptides of SEQUENCE ID NO:'s 1 to 11, that is capable of reducing post-prandial blood glucose levels, and increasing insulin secretion in humans, is also described.
    Type: Grant
    Filed: May 12, 2015
    Date of Patent: July 17, 2018
    Assignees: University College Dublin, National University Of Ireland, Dublin, University of Limerick
    Inventors: Lorraine Brennan, Aisling Robinson, Nessa Noronha, Dick Fitzgerald, Alice Nongonierma, Therese Holton, Helen Roche, J C Jacquier, Denis Shields, Eileen Gibney
  • Patent number: 9956425
    Abstract: Methods and compositions to controllably regulate cells at a target site. A quantum dot-targeting agent complex is administered to a patient in need of therapy, and the complex is stimulated using an implanted fiber optic system. In embodiments, the system includes an electrical sensor that detects and monitors electrical activity of the stimulated controllably regulated cells, and relays this information to a controller that can regulate further stimulation.
    Type: Grant
    Filed: January 21, 2014
    Date of Patent: May 1, 2018
    Inventor: Gholam A. Peyman
  • Patent number: 9943515
    Abstract: Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.
    Type: Grant
    Filed: January 21, 2016
    Date of Patent: April 17, 2018
    Assignee: Helsinn Healthcare SA
    Inventors: Fabio Trento, Sergio Cantoreggi, Giorgia Rossi, Roberta Cannella, Daniele Bonadeo
  • Patent number: 9896491
    Abstract: Novel oligopeptides, combinations thereof and fusion proteins composed of the above-mentioned oligopeptides are disclosed. Oligopeptides are homologous in amino acid sequence to the selected parts of the amino acid sequence of human myelin basic protein (MBP) and are capable to ameliorate the progression of multiple sclerosis by means of binding to and inactivation of epitope-specific anti MBP catalytic auto antibodies (ESAMBPCAA) involved into binding and catalytic degradation of MBP in course of progression of Multiple Sclerosis.
    Type: Grant
    Filed: April 11, 2012
    Date of Patent: February 20, 2018
    Assignee: LIFEBIO LABORATORIES LLC
    Inventors: Aleksey Anatolievich Belogurov, Alexandr Gabibovich Gabibov, Natalya Alexandrovna Ponomarenko
  • Patent number: 9873717
    Abstract: The invention relates to a novel thyrotropin releasing hormone (TRH) receptor subtype in human central nervous system (CNS) that is pharmacologically distinct from the TRH receptor subtype in human pituitary. The invention provides a means to understand how the central actions of TRH are mediated and to isolate and characterize the novel receptor, as well as methods applicable to research and development of diagnostic and therapeutic applications in human CNS disorders.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: January 23, 2018
    Assignee: THE PROVOST, FELLOWS, FOUNDATION SCHOLARS, AND THE OTHER MEMBERS OF BOARD, OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN
    Inventor: Julie Kelly
  • Patent number: 9868764
    Abstract: A peptide compound having a dipeptidyl peptidase-IV (DPPIV) inhibitory activity or a composition containing the peptide compound that can make a contribution to the prevention of the onset of pathology or the progression in diabetes mellitus patients or those at risk of diabetes mellitus can be provided according to the present invention by a simple method using, as a raw material, milt of a fishery product, which has been eaten for ages and has high safety. In the present invention, a peptide compound having a peptidyl peptidase-IV (DPPIV) inhibitory activity obtained in a hydrolysate of a milt protein source obtained from a fishery product is used as an active component of a composition for inhibiting DPPIV.
    Type: Grant
    Filed: May 19, 2014
    Date of Patent: January 16, 2018
    Assignee: Maruha Nichiro Corporation
    Inventors: Yoshinori Takahashi, Akira Kamata, Tatsuya Konishi
  • Patent number: 9790181
    Abstract: A method for producing (2S,5S)/(2R,5R)-5-hydroxypiperidine-2-carboxylic acid represented by formula (10) below: the method including removing the protecting group from the hydroxyl group in a compound represented by formula (7) below: (wherein P represents a protecting group, R3 represents an alkyl group containing 1 to 4 carbon atoms, and A represents an alkyl group containing 1 to 10 carbon atoms, an aryl group containing 6 to 12 carbon atoms, an alkyloxy group containing 1 to 4 carbon atoms, or an aralkyloxy group containing 7 to 20 carbon atoms) to synthesize a compound represented by formula (8) below: (wherein R3 represents an alkyl group containing 1 to 4 carbon atoms, and A represents an alkyl group containing 1 to 10 carbon atoms, an aryl group containing 6 to 12 carbon atoms, an alkyloxy group containing 1 to 4 carbon atoms, or an aralkyloxy group containing 7 to 20 carbon atoms).
    Type: Grant
    Filed: December 26, 2014
    Date of Patent: October 17, 2017
    Assignee: API CORPORATION
    Inventors: Jun Takehara, Masato Murai, Takashi Ohtani, Tomoko Maeda, Tsugihiko Hidaka
  • Patent number: 9745349
    Abstract: A cyclic peptide or a salt thereof of formula (1): X-Leu-Val-Y1-Y2 (1), where X is Lys, Arg, His, Ala, Gly, Ser, or Thr; and Y1 and Y2, which are identical to or different from each other, each represent a group represented by formula (2): where Ar1 represents an aromatic hydrocarbon group or an aromatic heterocyclic group; R1 represents a hydrogen atom, an alkyl group, a cycloalkyl group, a haloalkyl group, an aromatic hydrocarbon group, or an aromatic heterocyclic group; and n is an integer from 0 to 2. In the cyclic peptide has an ?-amino group at the amino terminus of the amino acid sequence which is linked, via a peptide bond, to the carboxyl group at the carboxyl terminus of the amino acid sequence.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: August 29, 2017
    Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCY
    Inventors: Motomu Kanai, Yohei Soma, Tadamasa Arai, Daisuke Sasaki, Yuki Kobayashi
  • Patent number: 9737526
    Abstract: An oromucosal solution comprising about 1-8% (w/v) apomorphine or a pharmaceutical acceptable salt thereof solubilised in a non-aqueous carrier containing at least about 50% (v/v) of propylene glycol. A small volume (25-250 ?L) of said solution containing about 1-12 mg apomorphine may be administered upon demand to treat motor fluctuations during off periods in patients suffering from Parkinson's disease. The solution may also be used for the treatment of sexual dysfunction.
    Type: Grant
    Filed: November 7, 2016
    Date of Patent: August 22, 2017
    Assignee: INNOTESTO BVBA
    Inventor: Franciscus Wilhelmus Henricus Maria Merkus
  • Patent number: 9669092
    Abstract: Inhibition of the VIP signaling pathway using VIP antagonists is contemplated. Methods of treating or preventing a viral infection comprising administering a VIP antagonist to a subject in need thereof are also contemplated.
    Type: Grant
    Filed: January 31, 2012
    Date of Patent: June 6, 2017
    Assignee: Emory University
    Inventors: Edmund K. Waller, Jian-Ming Li, Mohammad S. Hossain
  • Patent number: 9598475
    Abstract: The present invention relates to methods for preventing or treating neurological diseases, particularly brain diseases, and improving cognitive functions using a composition comprising stanniocalcin 2 as an active ingredient.
    Type: Grant
    Filed: September 3, 2013
    Date of Patent: March 21, 2017
    Assignee: Regeron, Inc.
    Inventors: Heejae Lee, Jong-Seon Byun, Kyunyoung Lee, Dahlkyun Oh
  • Patent number: 9464110
    Abstract: An acyl dipeptide derivative represented by the formula (1): wherein an acyl group represented by R1—CO— is a saturated or unsaturated, straight or branched chain acyl group having 2-24 carbon atoms, R2 and R3 are each independently a hydrogen atom, an OH group or an OR5 group, R5 is a saturated or unsaturated, straight or branched chain hydrocarbon group having 1-6 carbon atoms, and R4 is a hydrogen atom, or a saturated or unsaturated, straight or branched chain hydrocarbon group having 1-6 carbon atoms, or a salt thereof has a superior antimicrobial effect, and a composition containing the compound is superior in the sensory feel.
    Type: Grant
    Filed: February 23, 2015
    Date of Patent: October 11, 2016
    Assignee: AJINOMOTO CO., INC.
    Inventor: Takanori Sugimoto
  • Patent number: 9458217
    Abstract: This disclosure relates to the use of drugs to prevent graft versus host disease (GVHD) in a subject after, before, or during a hematopoietic stem cell transplant. In certain embodiments, the drugs are antagonist of vasoactive intestinal peptide signaling. In certain embodiments, the subject has a blood or bone marrow cancer or condition.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: October 4, 2016
    Assignee: Emory University
    Inventors: Edmund K. Waller, Cynthia R. Giver, Sravanti Rangaraju
  • Patent number: 9364449
    Abstract: Novel peptide/peptoid oligomers are disclosed that have a formula represented by the following formula Ia or Ib: The peptide/peptoid oligomers demonstrate the ability to inhibit fibrillization and oligomerization of A? and may be prepared as pharmaceutical compositions and used for the prevention or treatment of a variety of conditions in mammals, including humans, associated with A? oligomerization. The present peptidomimetic oligomers are particularly valuable for the treatment of subjects with AD.
    Type: Grant
    Filed: June 9, 2011
    Date of Patent: June 14, 2016
    Assignee: New York University
    Inventors: Martin J. Sadowski, Kent Kirshenbaum
  • Patent number: 9327011
    Abstract: Peptide 6 and in particular, Peptide 021, may be used to treat tauopathies, such as frontotemporal dementia with Parkinsonism linked to chromosome-17 (FTDP-17) tau, corticobasal degeneration, Pick disease, progressive supranuclear palsy, Guam Parkinsonism dementia complex, dementia pugilistica also known as traumatic encephalopathy or traumatic brain injury, ceroid neuronal lipofusinosis, Hallerworden Sptaz disease, Alzheimer's disease, and adults with Down syndrome.
    Type: Grant
    Filed: August 21, 2014
    Date of Patent: May 3, 2016
    Assignee: The Research Foundation For Mental Hygiene, Inc.
    Inventors: Khalid Iqbal, Inge Grundke-Iqbal
  • Patent number: 9290759
    Abstract: The invention provides optimized miRNA sequences and their therapeutic use. The invention provides optimized miRNA constructs for treatment of neurodegenerative diseases.
    Type: Grant
    Filed: August 25, 2011
    Date of Patent: March 22, 2016
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Asa Abeliovich, Hervé Rhinn, Toru Yamashita
  • Patent number: 9271975
    Abstract: Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: March 1, 2016
    Assignee: HELSINN HEALTHCARE SA
    Inventors: Fabio Trento, Sergio Cantoreggi, Giorgia Rossi, Roberta Cannella, Daniele Bonadeo
  • Patent number: 9249203
    Abstract: A neurotrophic peptide having the sequence VGDGGLFEKKL (SEQ ID NO: 1) may be used to help sustain local microenvironment after mild-to-moderate brain injury. Treatment with the peptide was shown to enhance differentiation of newly born progenitors in the dentate gyrus 30 days after injury and to promote neuronal maturation and survival that is not seen naturally after traumatic brain injuries.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: February 2, 2016
    Assignee: The Research Foundation For Mental Hygiene, Inc.
    Inventors: Khalid Iqbal, Inge Grundke-Iqbal
  • Patent number: 9234036
    Abstract: The present invention provides agents for inhibiting binding of a pro-neurotrophin to a Vps1 Op-domain receptor, in particular the binding of a pro-NGF or a pro-BDNF to a Sortilin receptor. The invention thus provides agents for the manufacture of a medicament, for treating and/or preventing disease or disorders such as but not limited to neurological, neuropsychiatric and ocular diseases, disorders, and degeneration as well as obesity, diabetes, pain and/or nociception in an individual.
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: January 12, 2016
    Assignee: H. Lundbeck A/S
    Inventors: Olav Michael Anderson, Anders Nykjaer
  • Patent number: 9200082
    Abstract: Embodiments of the invention are directed to fibrillar adjuvants. For example, epitopes assembled by a synthetic peptide domain into nanofibers comprising a ?-fibrillization peptide may elicit high antibody titers in the absence of any adjuvant. In certain embodiments, multiple different antigens may be integrated into polypeptide nanofibers, providing biomaterials with modular and precise composition of bioactive proteins.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: December 1, 2015
    Assignee: The University of Chicago
    Inventors: Joel Collier, Gregory Hudalla
  • Patent number: 9186357
    Abstract: Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.
    Type: Grant
    Filed: November 1, 2013
    Date of Patent: November 17, 2015
    Assignee: HELSINN HEALTHCARE SA
    Inventors: Fabio Trento, Sergio Cantoreggi, Giorgia Rossi, Roberta Cannella, Daniele Bonadeo
  • Patent number: 9173862
    Abstract: The present invention provides methods for treating or limiting development of age-related macular degeneration, as well as methods for identifying compound suitable for such use.
    Type: Grant
    Filed: April 17, 2009
    Date of Patent: November 3, 2015
    Assignee: Arizona Board of Regents, a Body Corporate of the State of Arizona, Acting for and on Behalf of the University of Arizona
    Inventors: Brian McKay, John A. Martens
  • Patent number: 9095557
    Abstract: The present invention is directed to a pharmaceutical composition comprising a Compound (a) of a class of peptide Compounds and at least one further Compound (b) for the prevention, alleviation or/and treatment of epileptic seizures.
    Type: Grant
    Filed: November 14, 2013
    Date of Patent: August 4, 2015
    Assignee: UCB PHARMA GMBH
    Inventor: Thomas Stöhr
  • Patent number: 9050302
    Abstract: One embodiment of the present invention is to improve the safety and efficacy of the administration of GHB or a salt thereof to a patient. It has been discovered that the concomitant administration of an MCT inhibitor, such as diclofenac, valproate, or ibuprofen, will affect GHB administration. For example, it has been discovered that diclofenac lowers the effect of GHB in the body, thereby potentially causing an unsafe condition. Furthermore, it has been discovered that valproate increases the effect of GHB on the body, thereby potentially causing an unsafe condition.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: June 9, 2015
    Assignee: Jazz Pharmaceuticals Ireland Limited
    Inventor: Mark Eller
  • Patent number: 9051273
    Abstract: Phosphodiesterase 4 inhibitors without vomiting of the present invention are compounds or prodrugs or solvates represented by formula (I) wherein R1 is an independent methoxy, bromine and substituted aryl; X is an optionally substituted six-membered heterocyclic ring; Y is —(CH2)n—, —NH(CH2)n—, and —NH(CH2)n—O—, wherein n is any value among 0, 1, 2 and 3; Z is an optionally substituted aromatic ring or an optionally substituted heteroaromatic ring. Phosphodiesterase 4 inhibitor without vomiting of the present invention are novel biphenyl series PDE4D inhibitors, and can be applied to treat depression and Alzheimer's disease, improve cognitive ability and avoid vomiting.
    Type: Grant
    Filed: August 25, 2012
    Date of Patent: June 9, 2015
    Inventors: Jiangping Xu, Zhongzhen Zhou
  • Patent number: 9044428
    Abstract: The present invention relates to peptide compounds that are capable of stimulating neuronal differentiation, neurite outgrowth and survival of neural cells, and enhancing synaptic plasticity, learning and memory, methods of treating diseases and conditions of nervous system by administration of compositions comprising said compounds. The compounds and compositions of the invention include peptide sequences that are derived from the sequence of human erythropoietin or proteins that are homologous of human erythropoietin.
    Type: Grant
    Filed: November 19, 2012
    Date of Patent: June 2, 2015
    Assignee: Neoloch ApS
    Inventors: Vladimir Berezin, Elisabeth Bock
  • Publication number: 20150147385
    Abstract: Compositions and methods for the treatment of proliferative disorders including proliferative such as breast, uterine cervical, ophthalmic, and pancreatic cancer by the administration of intravenous synthetic curcumin (S-curcumin) are disclosed herein.
    Type: Application
    Filed: November 21, 2014
    Publication date: May 28, 2015
    Inventor: Lawrence Helson
  • Patent number: 9040485
    Abstract: Embodiments of this invention include synthetic compounds (NRP analogues) of peptides termed neural regeneration peptides (NRPs). NRP analogues are made by substituting amino acids in the native peptide sequence, modifying amino acids chemically, by replacing amino acids with synthetic moieties, by stabilizaing ?-turns, acetylation of terminal glycine residues or by cyclization. NRP analogues can be used to treat a variety of conditions involving degeneration of neural cells, and includes treating disorders of the nervous system, including peripheral neuropathy, multiple sclerosis, diabetic peripheral neuropathy, neurotoxin-induced neurodegeneration, and amyotrophic lateral sclerosis.
    Type: Grant
    Filed: October 15, 2012
    Date of Patent: May 26, 2015
    Assignee: CURONZ HOLDINGS COMPANY LIMITED
    Inventors: Paul William Richard Harris, Margaret Ann Brimble, Frank Sieg
  • Publication number: 20150141345
    Abstract: This invention provides novel compounds and methods for promoting cell survival and/or plasticity, especially in neuronal cells, by targeting the microtubule End Binding (EB) proteins and other associated proteins (e.g., drebrin). Methods for identifying potential modulators of cell death/plasticity are also described.
    Type: Application
    Filed: March 12, 2013
    Publication date: May 21, 2015
    Inventors: Illana Gozes, Saar Oz, Jacqueline Woang Cheing Tiong
  • Publication number: 20150140127
    Abstract: Provided is a method for detecting injury to the brain comprising: a) determining the level of a tight junction (TJ) protein in exosomes isolated from a test sample from a subject, wherein the TJ protein is occludin, claudin-3, claudin-5, claudin-12, ZO-1, ZO-2, ZO-3, JAM-A, JAM-B or JAM-C, or any combination thereof; b) comparing the level of the TJ protein in the test sample to the level of the TJ protein in a control sample, wherein an elevated level of the TJ protein in the test sample relative to the level of the TJ protein in the control sample indicates that the subject has an injury to the brain.
    Type: Application
    Filed: June 25, 2013
    Publication date: May 21, 2015
    Applicant: TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Servio H. Ramirez, Slava Rom, Yuri Persidsky
  • Patent number: 9034824
    Abstract: Potent compounds having combined antioxidant, anti-inflammatory, anti-radiation and metal chelating properties are described. Short peptides having these properties, and methods and uses of such short peptides in clinical and cosmetic applications are described.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: May 19, 2015
    Assignees: ONEDAY—BIOTECH AND PHARMA LTD., YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
    Inventors: Josef Mograbi, Daphne Atlas, Shoshana Keynan
  • Publication number: 20150132296
    Abstract: Compositions and methods useful for the treatment of neuromyelitis optica (NMO) or neuromyelitis optica spectrum disorder (NMOSD) are disclosed.
    Type: Application
    Filed: November 12, 2014
    Publication date: May 14, 2015
    Inventors: Colin Broom, Jeffrey Dayno
  • Publication number: 20150132365
    Abstract: The present invention relates to a fermented infant formulae comprising non digestible oligosaccharides for improving intestinal tract health by decreasing protein digestive effort, by decreasing the amount of endogenously formed proteases concomitant with an increased protein digestion, and a reduced protein fermentation.
    Type: Application
    Filed: June 14, 2013
    Publication date: May 14, 2015
    Applicant: N.V. Nutricia
    Inventors: Thomas Ludwig, Sylvie Huybers, Evan Abrahamse, Houkje Bouritius
  • Publication number: 20150133388
    Abstract: A method of inhibiting, reducing, and/or treating pathological apoptosis and/or protein aggregation in a subject includes administering to the subject an amount of a therapeutic polypeptide effective to inhibit, reduce, and/or treat the pathological apoptosis and/or protein aggregation. The therapeutic polypeptide including at least one of acetylated ?A-crystallin, acetylated ?B-crystallin, acetylated fragments thereof having molecular chaperone activity, and/or polypeptide mimetics thereof that can inhibit pathological protein aggregation and/or pathological apoptosis.
    Type: Application
    Filed: January 20, 2015
    Publication date: May 14, 2015
    Inventors: Ram Nagaraj, Rooban B. Nahomi
  • Publication number: 20150133387
    Abstract: Soluble proteins, e.g. Hevin, can trigger synapse formation; and other soluble proteins, e.g. SPARC antagonize this activity. Such proteins are synthesized in vitro and in vivo by astrocytes. Methods are provided for protecting or treating an individual suffering from adverse effects of deficits in synaptogenesis, or from undesirably active synaptogenesis.
    Type: Application
    Filed: September 15, 2014
    Publication date: May 14, 2015
    Inventors: Benjamin A. Barres, Cagla Eroglu
  • Publication number: 20150133367
    Abstract: The present invention includes a novel class of highly specific protease inhibitors. In one embodiment, the inhibitors of the invention are ?-helical in structure. In another embodiment, the present invention represents the first demonstration of a highly specific cysteine protease inhibitor.
    Type: Application
    Filed: April 26, 2013
    Publication date: May 14, 2015
    Inventor: Doron C. Greenbaum
  • Patent number: 9023789
    Abstract: The invention relates to polypeptides comprising an amino acid sequence which is an analog of human amylin, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments.
    Type: Grant
    Filed: September 24, 2013
    Date of Patent: May 5, 2015
    Assignee: Novo Nordisk A/S
    Inventors: Kirsten Dahl, Lauge Schaeffer, Thomas Kruse
  • Patent number: 9023800
    Abstract: Isolated DJ-1 related peptides are disclosed and pharmaceutical compositions comprising same for treating oxidative stress-related disorder.
    Type: Grant
    Filed: April 23, 2012
    Date of Patent: May 5, 2015
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Daniel Offen, Nirit Lev, Eldad Melamed
  • Publication number: 20150111828
    Abstract: The invention relates to compounds having either agonist or antagonist activities for the neurotrophins NGF and BDNF and represented by monomeric or dimeric substituted dipeptides that are analogs of the exposed portions of loop 1 or loop 4 regions of these neurotrophins near or at a beta-turn of the respective loop. N-acylated substituents of these dipeptides are biostereoisomers of the amino acid residues preceding these dipeptide sequences in the neurotrophin primary structure. The dimeric structure is produced advantageously by using hexamethylenediamine to which dipeptides are attached via their carboxyl groups. The claimed compounds displayed neuroprotective and differentiation-inducing activities in cellular models and enhanced the amount of phosphorylated tyrosine kinase A and the heat shock proteins Hsp32 and Hsp70 in the concentration range of 10?9 to 10?5 M.
    Type: Application
    Filed: August 15, 2014
    Publication date: April 23, 2015
    Applicant: UCHREZHDENIE ROSSIISKOI AKADEMII MEDITSYNSKIKH NAUK NAUCHNO-ISSLEDOVATELSKY INSTITUT FARMAKOLOGII
    Inventors: Sergey Borisovich SEREDENIN, Alexandrovna Tatyana GUDASHEVA
  • Publication number: 20150099693
    Abstract: The present invention relates to a peptide with anti-inflammatory activity, wherein the peptide comprises at least one amino acid sequence among SEQ ID NO: 2 to SEQ ID NO: 179, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The present invention also relates to an inflammatory composition comprising the above mentioned peptides. According to the present invention, the peptides that have at least one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 179 shows outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising the peptides of this invention can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Application
    Filed: March 15, 2013
    Publication date: April 9, 2015
    Applicants: KAEL-GEMVAX CO., LTD., GEMVAX-AS
    Inventors: Sang Jae Kim, Kyun Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Bum Joon Kim
  • Publication number: 20150099706
    Abstract: Methods and compositions used in treating ischemic stroke using a recombinant DR?-MOG-35-55 construct are disclosed. The disclosed methods involve administering a pharmaceutical composition comprising DR?-MOG-35-55 and a pharmaceutically acceptable carrier to a subject that has had or is at risk of developing ischemic stroke.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 9, 2015
    Inventors: Halina Offner-Vandenbark, Nabil Alkayed, Arthur A. Vandenbark
  • Patent number: 8999927
    Abstract: Described herein is the identification of primate-specific glial cell line-derived neurotrophic factor opposite strand (GDNFOS) transcripts and encoded peptides. In particular embodiments, provided herein are three GDNFOS antisense transcripts, referred to as GDNFOS-1, GDNFOS-2 and GDNFOS-3. The GDNFOS-3 transcript encodes an ORF of 105 amino acids. Compositions comprising the GDNFOS transcripts and peptides are also provided by the present disclosure. Further provided are methods of treating a neurodegenerative or peripheral organ disease in a subject by administering a therapeutically effective amount of the disclosed GDNFOS nucleic acid molecules, peptides or compositions.
    Type: Grant
    Filed: April 2, 2013
    Date of Patent: April 7, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventor: Qing-Rong Liu
  • Patent number: 8993721
    Abstract: Described herein is an isolated polypeptide which is capable of specifically targeting apoptotic cells undergoing apoptosis and consists of the sequence (I): Cys-X1-Val-Ala-Pro-X2 (I), wherein X1 is an amino acid with polar uncharged side chain and X2 is an amino acid with positive charged side chain. The isolated polypeptide of the present invention may be useful for detecting apoptotic cells, as well as detecting and imaging apoptotic cells in tumor tissue, apoptotic myocardial cells in myocardial infarction tissue, apoptotic nerve cells in stroke tissue, and arteriosclerosis site; the polypeptide is useful for targeted drug delivery thereto.
    Type: Grant
    Filed: May 9, 2012
    Date of Patent: March 31, 2015
    Inventors: Byung Heon Lee, In San Kim
  • Publication number: 20150087594
    Abstract: The present invention relates to a method of deriving an induced neural stem cell (iNCS) by nuclear reprogramming of a somatic cell, wherein the method comprises a step of contacting the somatic cell with Oct4 protein or a functionally equivalent analogue, variant or fragment thereof for a limited time period, as well as an induced neural stem cell obtained by this method.
    Type: Application
    Filed: February 27, 2013
    Publication date: March 26, 2015
    Inventors: Frank Oliver Stefan Edenhoffer, Philipp Woersdoerfer, Yenal Bernhard Lakes, Marc-Christian THIER, Oliver Bruestle
  • Publication number: 20150086481
    Abstract: GUCY2C receptor ligands conjugated to diagnostic and/or therapeutic moieties, methods of making such GUCY2C receptor ligands conjugates, and methods of using such GUCY2C receptor ligands conjugates, such as in the diagnosis and/or treatment of Parkinson's disease, are described.
    Type: Application
    Filed: July 27, 2012
    Publication date: March 26, 2015
    Applicant: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Yosif Ganat, Lorenz Studer